Penserra Capital Management LLC Allakos Inc. Transaction History

Penserra Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$8.55 - $111.89 $10,559 - $138,184	-1,235 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$76.53 - $110.43 $1,147 - $1,656	15 Added 1.23%	1,235 $130,000
Q2 2021 Aug 12, 2021	BUY	$85.37 - $114.1 $2,987 - $3,993	35 Added 2.95%	1,220 $104,000
Q1 2021 May 13, 2021	SELL	$109.73 - $153.66 $2,743 - $3,841	-25 Reduced 2.07%	1,185 $136,000
Q4 2020 Feb 12, 2021	BUY	$79.58 - $152.45 $63,186 - $121,045	794 Added 190.87%	1,210 $169,000
Q3 2020 Nov 13, 2020	BUY	$66.43 - $90.99 $27,634 - $37,851	416 New	416 $33,000
Q4 2018 Feb 06, 2019	SELL	$31.59 - $62.65 $357,598 - $709,198	-11,320 Closed	0 $0
Q3 2018 Nov 05, 2018	BUY	$31.25 - $47.64 $353,750 - $539,284	11,320 New	11,320 $509,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.